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Abstract
Background The National Early Warning Score (NEWS2) is currently recommended in
the United Kingdom for risk-stratification of COVID-19 patients, but little is
known about its ability to detect severe cases. We aimed to evaluate NEWS2
for prediction of severe COVID-19 outcome and identify and validate a set of
blood and physiological parameters routinely-collected at hospital admission
to improve upon use of NEWS2 alone for medium-term risk stratification.
Methods Training cohorts comprised 1276 patients admitted to King’s College
Hospital National Health Service (NHS) Foundation Trust with COVID-19
disease from 1st March to 30th April 2020. External validation cohorts
included 6237 patients from five UK NHS Trusts (Guys and St Thomas’
Hospitals, University Hospitals Southampton, University Hospitals Bristol
and Weston NHS Foundation Trust, University College London Hospitals,
University Hospitals Birmingham), one hospital in Norway (Oslo University
Hospital), and two hospitals in Wuhan, China (Wuhan Sixth Hospital and
Taikang Tongji Hospital). The outcome was severe COVID-19 disease
(transfer to intensive care unit (ICU) or death) at 14 days after hospital
admission. Age, physiological measures, blood biomarkers, sex, ethnicity and
comorbidities (hypertension, diabetes, cardiovascular, respiratory and kidney
diseases) measured at hospital admission were considered in the models.
Results A baseline model of ‘NEWS2 + age’ had poor-to-moderate discrimination for
severe COVID-19 infection at 14 days (area under receiver operating
characteristic curve (AUC) in training cohort = 0.700; 95% Confidence
Interval (CI): 0.680, 0.722; Brier score = 0.192; 95% CI: 0.186, 0.197). A
supplemented model adding eight routinely-collected blood and
physiological parameters (supplemental oxygen flow rate, urea, age, oxygen
saturation, C-reactive protein, estimated glomerular filtration rate, neutrophil
count, neutrophil/lymphocyte ratio) improved discrimination (AUC = 0.735;
95% CI: 0.715, 0.757) and these improvements were replicated across seven
UK and non-UK sites. However, there was evidence of miscalibration with
the model tending to underestimate risks in most sites.
Conclusions NEWS2 score had poor-to-moderate discrimination for medium-term
COVID-19 outcome which raises questions about its use as a screening tool
at hospital admission. Risk stratification was improved by including readily
available blood and physiological parameters measured at hospital admission,
but there was evidence of miscalibration in external sites. This highlights the
need for a better understanding of the use of early warning scores for
COVID.
Keywords: NEWS2 score, blood parameters, COVID-19, prediction model.
KEY MESSAGES
 The National Early Warning Score (NEWS2), currently recommended for
stratification of severe COVID-19 disease in the United Kingdom, showed poor-
to-moderate discrimination for medium-term outcomes (14-day transfer to
intensive care unit (ICU) or death) among COVID-19 patients.
 Risk stratification was improved by the addition of routinely-measured blood and
physiological parameters routinely at hospital admission (supplemental oxygen,
urea, oxygen saturation, C-reactive protein, estimated glomerular filtration rate,
neutrophil count, neutrophil/lymphocyte ratio) which provided moderate
improvements in a risk stratification model for 14-day ICU/death.
 This improvement over NEWS2 alone was maintained across multiple hospital
trusts but the model tended to be miscalibrated with risks of severe outcomes
underestimated in most sites.
 We benefited from existing pipelines for informatics at King’s College Hospital
such as CogStack that allowed rapid extraction and processing of electronic health
records. This methodological approach provided rapid insights and allowed us to
overcome the complications associated with slow data centralisation approaches.
BACKGROUND
As of 9th December 2020, there have been >67 million confirmed cases of COVID-19 disease
worldwide[1]. While approximately 80% of infected individuals have mild or no
symptoms[2], some develop severe COVID-19 disease requiring hospital admission. Within
the subset of those requiring hospitalisation, early identification of those who deteriorate and
require transfer to an intensive care unit (ICU) for organ support or may die is vital.
Currently available risk scores for deterioration of acutely-ill patients include (i) widely-used
generic ward-based risk indices such as the National Early Warning Score (NEWS2)[3], (ii)
the Modified Sequential Organ Failure Assessment (mSOFA)[4] and Quick Sequential Organ
Failure Assessment[5] scoring systems; and (iii) the pneumonia-specific risk index, CURB-
65[6] which combines physiological observations with limited blood markers and
comorbidities. NEWS2 is a summary score of six physiological parameters or ‘vital signs’
(respiratory rate, oxygen saturation, systolic blood pressure, heart rate, level of
consciousness, temperature and supplemental oxygen dependency) used to identify patients
at risk of early clinical deterioration in the United Kingdom (UK) National Health Service
(NHS) hospitals[7, 8] and primary care. Some components (in particular, patient temperature,
oxygen saturation and supplemental oxygen dependency) have been associated with COVID-
19 outcomes[2], but little is known about their predictive value for COVID-19 disease
severity in hospitalised patients[9]. Additionally, a number of COVID-19-specific risk
indices are being developed[10, 11] as well as unvalidated online calculators[12] but
generalisability is unknown[13]. A Chinese study has suggested a modified version of
NEWS2 with addition of age only[14] but without any data on performance. With near
universal usage of NEWS2 in UK NHS Trusts since March 2019[15], a minor adaptation to
NEWS2 would be relatively easy to implement.
As the SARS-Cov2 pandemic has progressed a number of risk prediction models to support
clinical decisions, triage and care in hospitalised patients have been proposed[13]
incorporating potentially useful blood biomarkers[2, 16–19]. These include neutrophilia and
lymphopenia, particularly in older adults[11, 18, 20, 21], neutrophil-to-lymphocyte ratio[22],
C-reactive Protein (CRP) [13] and lymphocyte-to-CRP ratio[22],  markers of liver and
cardiac injury such as alanine aminotransferase (ALT), aspartate aminotransferase (AST) and
cardiac troponin[23] and elevated D-dimers, ferritin and fibrinogen [2, 6, 8].
Our aim is to evaluate the NEWS2 score and identify which clinical and blood biomarkers
routinely measured at hospital admission can improve medium-term risk stratification of
severe COVID-19 outcome at 14 days from hospital admission. Our specific objectives were:
1 To explore independent associations of routinely measured physiological and blood
parameters (including NEWS2 parameters) at hospital admission with disease
severity (ICU admission or death at 14 days from hospital admission), adjusting for
demographics and comorbidities;
2 To develop a prediction model for severe COVID-19 outcomes at 14 days combining
multiple blood and physiological parameters.
3 To compare the discrimination, calibration and clinical utility of the resulting model
with NEWS2 score and age alone using (i) internal validation; (ii) external validation
at seven UK and international sites.
A recent systematic review found that most existing prediction models for COVID-19 had
high risk of bias due to non-representative samples, model overfitting, or poor reporting[13].
The analyses presented here build upon our earlier work[24] which suggested that adding age
and common blood biomarkers to the NEWS2 score could improve risk stratification in
patients hospitalized with COVID-19. While incorporating external validation, this
preliminary work was limited in that the training sample comprised 439 patients (the cohort
available at the time of model development). In the present study we (i) expand the cohort
used for model development to all 1276 patients at King’s College Hospital (KCH); (ii) use
hospital admission (rather than symptom onset) as the index date; (iii) consider shorter-term
outcomes (3-day ICU/death);  (iv) improving the reporting of model calibration and clinical
utility; and (v) increase the number of external sites from three to seven.
METHODS
Study cohorts
The KCH training cohort (n=1276) was defined as all adult inpatients testing positive for
severe acute respiratory syndrome coronavirus 2 (SARS-Cov2) by reverse transcription
polymerase chain reaction (RT-PCR) between 1st March to 31st April 2020 at two acute
hospitals (King’s College Hospital and Princess Royal University Hospital) in South East
London (UK) of Kings College Hospital NHS Foundation Trust (KCH). All patients included
in the study had symptoms consistent with COVID-19 (e.g. cough, fever, dyspnoea, myalgia,
delirium, diarrhoea). For external validation purposes we used seven cohorts:
1 Guys and St Thomas’ Hospital NHS Foundation Trust (GSTT) of 988 cases (3rd
March 2020 to 26th August 2020)
2 University Hospitals Southampton NHS Foundation Trust (UHS) of 633 cases (7th
March to 6th June 2020)
3 University Hospitals Bristol and Weston NHS Foundation Trust (UHBW) of 190
cases (12th March to 11th June 2020)
4 University College Hospital London (UCH) of 411 cases (1st February to 30th April
2020).
5 University Hospitals Birmingham (UHB) of 1037 cases (1st March to 31st June 2020).
6 Oslo University Hospital (OUH) of 163 cases (6th March to 13th June 2020).
7 Wuhan Sixth Hospital and Taikang Tongji Hospital of 2815 cases (4th February 2020
to 30th March 2020).
Data were extracted from structured and/or unstructured components of electronic health
records (EHR) in each site as detailed below.
Measures
Outcome. For all sites, the outcome was severe COVID-19 disease at 14 days following
hospital admission, categorised as transfer to ICU/death (WHO-COVID-19 Outcomes Scales
6-8) vs. not transferred to ICU/death (Scales 3-5) [25]. For nosocomial patients (patients with
symptom onset after hospital admission) the endpoint was defined as 14 days after symptom
onset. Dates of hospital admission, symptom onset, ICU transfer and death were extracted
from electronic health records or ascertained manually by a clinician.
Blood and physiological parameters. We included blood and physiological parameters that
were routinely obtained at hospital admission which are routinely available in a wide range of
national and international hospital and community settings. Measures available for fewer than
30% of patients were not considered (including Troponin-T, Ferritin, D-dimers and glycated
haemoglobin (HbA1c), Glasgow Coma Scale score). We excluded creatinine since this
parameter correlates highly (r > 0.8) with, and is used in the derivation of, estimated
glomerular filtration rate. We excluded white blood cell count (WBCs) which is highly
correlated with neutrophil and lymphocyte counts.
The candidate blood parameters therefore comprised: albumin (g/L), C-reactive protein
(CRP; mg/L), estimated Glomerular Filtration Rate (GFR; mL/min), Haemoglobin (g/L),
lymphocyte count (x 109/L), neutrophil count (x 109/L), and platelet count (PLT; x‌‌ 109/L),
neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-CRP ratio[22], and urea (mmol/L).
The candidate physiological parameters included the NEWS2 total score, as well as the
following parameters: respiratory rate (breaths per minute), oxygen saturation (%),
supplemental oxygen flow rate (L/min), diastolic blood pressure (mmHg), systolic blood
pressure (mmHg), heart rate (beats/min), temperature (°C), and consciousness (Glasgow
Coma Scale; GCS). For all parameters we used the first available measure up to 48 hours
following hospital admission.
Demographics and comorbidities. Age, sex, ethnicity and comorbidities were considered.
Self-defined ethnicity was categorised as White vs. non-White (Black, Asian, or other
minority ethnic) and patients with ethnicity recorded as ‘unknown/mixed/other’ were
excluded (n=316; 25%). Binary variables were derived for comorbidities: hypertension,
diabetes, heart disease (heart failure and ischemic heart disease), respiratory disease (asthma
and chronic obstructive pulmonary disease (COPD)) and chronic kidney disease.
Data Processing
King’s College Hospital
Data were extracted from the structured and unstructured components of the electronic health
record (EHR) using natural language processing (NLP) tools belonging to the CogStack
ecosystem[26], namely MedCAT[27] and MedCATTrainer[28]. The CogStack NLP pipeline
captures negation, synonyms, and acronyms for medical SNOMED-CT (Systematised
Nomenclature of MedicineClinical Terms) concepts as well as surrounding linguistic context
using deep learning and long short-term memory networks. MedCAT produces unsupervised
annotations for all SNOMED-CT concepts (Additional file 1: Table S1) under parent terms
Clinical Finding, Disorder, Organism, and Event with disambiguation, pre-trained on
MIMIC-III[29]. Starting from our previous model[30], further supervised training improved
detection of annotations and meta-annotations such as experiencer (is the annotated concept
experienced by the patient or other), negation (is the concept annotated negated or not) and
temporality (is the concept annotated in the past or present) with MedCATTrainer. Meta-
annotations for hypothetical, historical and experiencer were merged into “Irrelevant”
allowing us to exclude any mentions of a concept that do not directly relate to the patient
currently. Performance of the NLP pipeline for comorbidities mentioned in the text was
evaluated on 4343 annotations in 146 clinical documents by a clinician (JT). F1 scores,
precision, and recall are presented in Additional file 2: Table S2.
Guy’s and St Thomas NHS Foundation Trust (GSTT)
Electronic health records from all patients admitted to Guy’s and St Thomas NHS Foundation
Trust who had a positive COVID-19 test result between the 3rd of March and 21st of May
2020, inclusive, were identified. Data were extracted using structured queries from six
complementary platforms and linked using unique patient identifiers. Data processing was
performed using Python 3.7 [31]. The process and outputs were reviewed by a study
clinician.
University Hospitals Southampton (UHS)
Data were extracted from the structured components of the UHS CHARTS EHR system and
data warehouse. Data was transformed to the required format for validation purposes using
Python 3.7 [31]. Diagnosis and comorbidity data of interest were gathered from ICD-10
(International Statistical Classification of Diseases) coded data. No unstructured data
extraction was required for validation purposes. The process and outputs were reviewed by
an experienced clinician prior to analysis.
University Hospitals Bristol and Weston NHS Foundation Trust (UHBW)
Data were extracted from UHBW electronic health records system (Medway). ICD-10 codes
were used for diagnosis and comorbidity data. Data were transformed in line with project
specifications and exported for analysis in Python 3.7 [31].
University College Hospital London (UCH)
Dates of hospital admission, symptom onset, ICU transfer and death were extracted from
electronic health records. The outcome (14 day ICU/death) was defined in UCLH as
“initiation of ventilatory support (continuous positive airway pressure, non-invasive
ventilation, high flow nasal cannula oxygen, invasive mechanical ventilation or
extracorporeal membrane oxygenation) or death” which is consistent WHO-COVID-19
Outcomes Scales 6-8.
Wuhan cohort
Demographic, premorbid conditions, clinical symptoms or signs at presentation, laboratory
data, treatment and outcome data were extracted from electronic medical records using a
standardised data collection form by a team of experienced respiratory clinicians, with double
data checking and involvement of a third reviewer where there was disagreement.
Anonymised data was entered into a password-protected computerised database.
University Hospitals Birmingham (UHB)
Dates of hospital admission, symptom onset, ICU transfer and death were extracted from
electronic health records using the Prescribing Information and Communications System
(PICS) system. The extracted data was transformed to the required format for validation
purposes using Python 3.8 [31]. Diagnosis and comorbidity data of interest were gathered
from ICD-10 coded data. The outcomes (3 and 14 day ICU/death) were defined consistent
with WHO-COVID-19 Outcomes Scales 6-8.
Oslo University Hospital (OUH)
All admitted patients with confirmed COVID-19 by positive SARS-CoV2 PCR were
included in a quality registry. Data input into the register was manual. Register data was
supplemented with test results from the laboratory information system (LIS) by matching
exported Excel files from the register with exported Excel files from LIS. The fidelity of the
match was checked against the original data source manually for a small number of patients.
Only patients with symptoms consistent with COVID-19 were included in the study.
Statistical analyses
All continuous parameters were winsorized (at 1% and 99%) and scaled (mean = 0; standard
deviation = 1) to facilitate interpretability and comparability[32]. Logarithmic or square-root
transformations were applied to skewed parameters. To explore independent associations of
blood and physiological parameters with 14-day ICU/death (Objective 1) we used logistic
regression with Firth’s bias reduction method[33]. Each parameter was tested independently,
adjusted for age and sex (Model 1) and then additionally adjusted for comorbidities (Model
2). P-values were adjusted using the Benjamini-Hochberg procedure to keep the False
Discovery Rate (FDR) at 5%[34].
To evaluate NEWS2 and identify parameters that could improve prediction of severe
COVID-19 outcomes (Objectives 2 and 3) we used regularized logistic regression with a
LASSO (Least Absolute Shrinkage and Selection Operator) estimator that shrinks parameters
according to their variance, reduces overfitting, and enables automatic variable selection[35].
The optimal degree of regularization was determined by identifying a tuning parameter λ
using cross-validation. To avoid overfitting and to reduce the number of false positive
predictors, λ was selected to give a model with area under the receiver operating
characteristic curve (AUC) one standard error below the ‘best’ model. To evaluate the
predictive performance of our model on new cases of the same underlying population
(internal validation), we performed nested cross-validation (10 folds for inner loop; 10
folds/1000 repeats for outer loop). Discrimination was assessed using AUC and Brier score.
Missing feature information was imputed using k-Nearest Neighbours (kNN) imputation
(k=5). All steps (feature selection, winsorizing, scaling, and kNN imputation) were
incorporated within the model development and selection process to avoid data leakage that
would otherwise result in optimistic performance measures[36]. All analyses were conducted
with Python 3.8 [31] using the statsmodels[37] and Scikit-Learn[38] packages.
We evaluated the transportability of the derived regularized logistic regression model in
external validation samples from GSTT (n=988), UHS (n=633), UHBW (n=190), UCH
(n=411), UHB (n=1037), OUH (n=163), and Wuhan (n=2815). Validation used LASSO
logistic regression models trained on the KCH training sample, with code and pre-trained
models shared via GitHub1. Models were assessed in terms of discrimination (AUC,
sensitivity, specificity, Brier score), calibration, and clinical utility (decision curve analysis,
number needed to evaluate)[32, 39]. Moderate calibration was assessed by plotting model
1 https://github.com/ewancarr/NEWS2-COVID-19
predicted probabilities (x-axis) against observed proportions (y-axis) with LOESS (locally
estimated scatterplot smoothing) and logistic curves[40]. Clinical utility was assessed using
decision curve analysis where ‘net benefit’ was plotted against a range of threshold
probabilities. Unlike diagnostic performance measures, decision curves incorporate
preferences of the clinician and patient. The threshold probability (pt) is where the expected
benefit of treatment is equal to the expected benefit of avoiding treatment[41]. Net benefit
was calculated by counting the number of true positives (predicted risk > pt and experienced
severe COVID-19 outcome) and false positives (predicted risk > pt but did not experience
severe COVID-19 outcome), and using the below formula:
Our model was developed as a screening tool, to identify at hospital admission patients at risk
of more severe outcomes. The intended treatment for patients with a positive result from this
model would be further examination by a clinician, who would make recommendations
regarding appropriate treatment (e.g. earlier transfer to ICU, intensive monitoring, treatment).
We compared the decision curve from our model to two extreme cases of ‘treat none’ and
‘treat all’. The ‘treat none’ (i.e. routine management) strategy implies that no patients would
be selected for further examination by a clinician; the ‘treat all’ strategy (i.e. intensive
management) implies that all patients would undergo further assessment. A model is
clinically beneficial if the model-implied net benefit is greater than either the ‘treat none’ or
‘treat all’ strategies.
Since the intended strategy involves further examination by a clinician, and is therefore low
risk, our emphasis throughout is on avoiding false negatives (i.e. failing to detect a severe
case) at the expense of false positives. We therefore used thresholds of 30% and 20% (for 14-
day and 3-day outcomes, respectively) to calculate sensitivity and specificity. This gave a
better balance of sensitivity vs. specificity and reflected the clinical preference to avoid false
negatives for the proposed screening tool.
Sensitivity analyses
We conducted five sensitivity analyses. First, to explore the ability of NEWS2 to predict
shorter-term severe COVID-19 outcome we developed models for ICU transfer/death at 3
days following hospital admission. All steps described above were repeated, including
training (feature selection) and external validation. Second, following recent studies
suggesting sex differences in COVID-19 outcome[18] we tested interactions between each
physiological and blood parameter and sex using likelihood-ratio tests. Third, we repeated all
models with adjustment for ethnicity in the subset of individuals with available data for
ethnicity (n=960 in the KCH training sample). Fourth, to explore differences between
community-acquired vs. nosocomial infection, we repeated all models after excluding 153
nosocomial patients (n=1123). Finally, we considered an alternative baseline model of
‘NEWS2 only’. Our primary analyses used a baseline model of ‘NEWS2 + age’ because
NEWS2 is rarely used in isolation for prognostication and treatment decisions will
incorporate other patient characteristics such as age.
RESULTS
Descriptive analyses
The KCH training cohort comprised 1276 patients admitted with a confirmed diagnosis of
COVID-19 (from 1st March to 31st April 2020) of whom 389 (31%) and were transferred to
ICU or died within 14 days of hospital admission, respectively. The validation cohorts
comprised 6237 patients across seven sites. At UK NHS trusts, 30% to 42% of patients were
transferred to ICU or died within 14 days of admission. Disease severity was lower in the
Wuhan sample, where 4% were transferred to ICU or died. Table 1 presents the demographic
and clinical characteristics of the training and validation cohorts. The UK sites were similar
in terms of age and sex, with patients tending to be older (median age 59-74) and male (58%
to 63%) but varied in the proportion of patients of non-White ethnicity (from 10% at UHS to
40% at KCH and UCH). Blood and physiological parameters were broadly consistent across
UK sites.
(TABLE 1 about here)
Logistic regression models were used to assess independent associations between each
variable and severe COVID-19 outcome (ICU transfer/death) in the KCH cohort. Additional
file 3: Table S3 presents odds ratios adjusted for age and sex (Model 1) and comorbidities
(Model 2), sorted by effect size. Increased odds of transfer to ICU or death by 14 days were
associated with NEWS2 score, oxygen flow rate, respiratory rate, CRP, neutrophil count,
urea, neutrophil/lymphocyte ratio, heart rate, and temperature. Reduced odds of severe
outcomes were associated with lymphocyte/CRP ratio, oxygen saturation, estimated GFR,
and Albumin.
Evaluating NEWS2 score for prediction of severe COVID-19 outcome
Logistic regression models were used to evaluate a baseline model containing hospital
admission NEWS2 score and age for prediction of severe COVID-19 outcomes at 14 days.
Internally validated discrimination for the KCH training sample was moderate (AUC =
0.700; 95% Confidence Interval (CI): 0.680, 0.722; Brier score = 0.192; 0.186, 0.197; Table
2). Discrimination remained poor-to-moderate in UK validation sites (AUC = 0.623 to
0.729), but was moderate-to-good in Norway (AUC = 0.786) and Wuhan hospitals (AUC =
0.815) (Figures 1 and 2). Calibration was inconsistent with risks underestimated in some sites
(UHS, GSTT) and overestimated in others (UHBW, UHB; Figure 2).






14-day ICU/death AUC 0.700 [0.680, 0.722] 0.735 [0.715, 0.757]
Brier score 0.192 [0.186, 0.197] 0.183 [0.177, 0.189]
Sensitivity1 0.778 [0.747, 0.815] 0.735 [0.702, 0.772]
Specificity1 0.478 [0.445, 0.509] 0.592 [0.562, 0.621]
Notes.
1 Calculated at 30% probability threshold. AUC based on repeated, nested cross-
validation. (inner loop: 10 folds; outer loop = 10 folds/1000 repeats). Missing values
imputed at each outer loop with k-Nearest Neighbours (kNN) imputation.
Supplementing NEWS2 with routinely collected blood and physiological parameters
We considered whether routine blood and physiological parameters could improve risk
stratification for medium-term COVID-19 outcome (ICU transfer/death at 14 days). When
adding demographic, blood, and physiological parameters to NEWS2, nine features were
retained following LASSO regularisation, in order of effect size: NEWS2 score,
supplemental oxygen flow rate, urea, age, oxygen saturation, CRP, estimated GFR, neutrophil
count, neutrophil/lymphocyte ratio. Notably, comorbid conditions were not retained when
added in subsequent models, suggesting most of the variance explained was already captured
by the included parameters. Internally validated discrimination in the KCH training sample
was moderate (AUC = 0.735; 95% CI: 0.715, 0.757) but improved compared to ‘NEWS2 +
age’ (Table 3). This improvement over NEWS2 alone was replicated in validation samples
(Figure 1). The supplemented model continued to show evidence of substantial
miscalibration.
(FIGURE 1 about here)
(FIGURE 2 about here)
Sensitivity analyses
For the 3-day endpoint, 13% of patients at KCH (n=163) and between 16% and 29% of
patients in the UK and Norway were transferred to ICU or died (Table 1). The 3-day model
retained just two parameters following regularisation: NEWS2 score and supplemental
oxygen flow rate. For the baseline model (‘NEWS2 + age’) discrimination was moderate at
internal validation (AUC = 0.764; 95% CI: 0.737, 0.794; Additional file 4: Table S4) and
external validation (AUC = 0.673 to 0.755) but calibration remained poor (Additional file 5:
Figure S1). Moreover, the supplemented model (‘NEWS2 + oxygen flow rate’) showed
smaller improvements in discrimination compared to those seen at 14 days. For the KCH
training cohort internally validated AUC increased by 0.025: from 0.764 (95% CI: 0.737,
0.794) for ‘NEWS2 + age’ to 0.789 (0.763, 0.819) for the supplemented model (‘NEWS2 +
oxygen flow rate’). At external validation, improvements were modest (UHBW, OUH) or
negative (GSTT) in some sites; but more substantial in others (UHS, UCH). Moreover, model
calibration was considerably worse for the supplemented 3-day model (Additional file 5:
Figure S1).
We found no evidence of difference by sex (results not shown) and findings were consistent
when additionally adjusting for ethnicity in the subset of individuals with ethnicity data and
when excluding nosocomial patients (Additional file 6: Table S5).  Discrimination for the
alternative baseline model of ‘NEWS2 only’ (Additional file 7: Table S6) showed a similar
pattern of results as those for ‘NEWS2 + age’, except that improvements in discrimination
for the supplemented model (‘All features’) were larger in most sites.
Decision curve analysis
Decision curve analysis for the 14-day endpoint is presented in Figure 3. At KCH the
baseline model (‘NEWS2 + age’) offered small increments in net benefit compared to the
‘treat all’ and ‘treat none’ strategies for risk thresholds in the range 25% to 60%. This was
replicated in all validation cohorts except for UHBW and OUH where net benefit for
‘NEWS2 + age’ was lower than the ‘treat none’ strategy beyond the 40% risk threshold. The
supplemented model (‘All features’) improved upon ‘NEWS2 + age’ and the two default
strategies in most sites across the range 20% to 80%, except for (i) UHBW, where ‘treat
none’ was superior beyond thresholds of 55%; (ii) GSTT, where ‘treat all’ was superior up to
a threshold of 30% and no improvement was seen for supplemented model.
(FIGURE 3 about here)
For the 3-day endpoint the improvement in net benefit for the supplemented model over the
two default strategies was smaller, compared to improvements seen at 14 days (Additional
file 8: Figure S2). At three sites (UHBW, GSST and Wuhan) neither the baseline (‘NEWS2 +
age’) nor supplemented (‘All features’) models offered any improvement over the ‘treat all’
or ‘treat none’ strategies. At KCH and UHS net benefit for ‘NEWS2 + age’ was higher than
the default strategies for a range of risk thresholds, but was not increased further by the
supplemented (‘NEWS2 + oxygen flow rate’) model.
DISCUSSION
Principal findings
This study is among the first to systematically evaluate NEWS2 for severe COVID-19
outcome and carry out external validation at multiple international sites (five UK NHS
Trusts, one hospital in Norway, and two hospitals in Wuhan, China). We found that while
‘NEWS2 + age’ had moderate discrimination for short-term COVID-19 outcome (3-day ICU
transfer/death), it showed poor-to-moderate discrimination for medium-term outcome (14-
day ICU transfer/death). Thus, while NEWS2 may be effective for short-term (e.g. 24 hours)
prognostication, our results question its suitability as a screening tool for medium-term
COVID-19 outcome. Risk stratification was improved by adding routinely-collected blood
and physiological parameters, and discrimination in supplemented models was moderate-to-
good. However, the model showed evidence of miscalibration, with a tendency to
underestimate risks in external sites. The derived model for 14-day ICU transfer/death
included nine parameters: NEWS2 score, supplemental oxygen flow rate, urea, age, oxygen
saturation, CRP, estimated GFR, neutrophil count, neutrophil/lymphocyte ratio. Notably, pre-
existing comorbidities did not improve risk prediction and were not retained in the final
model. This was unexpected but may indicate that the effect of pre-existing health conditions
could be manifest through some of the included blood or physiological markers.
Overall, this study overcomes many of the factors associated with high risk of bias in the
development of prognostic models for COVID-19[13] and provides some evidence to support
the supplementation of NEWS2 for clinical decisions with these patients.
Comparison with other studies
A systematic review of 10 prediction models for mortality in COVID-19 infection[10] found
broad similarities with the features retained in our models, particularly regarding CRP and
neutrophil levels. However, existing prediction models suffer several methodological
weaknesses including overfitting, selection bias, and reliance on cross-sectional data without
accounting for censoring. Additionally, many existing studies have relied on single centre  or
ethnically homogenous Chinese cohorts, whereas the present study shows validation across
multiple  and diverse populations. A key strength of our study is the robust and repeated
external validation across national and international sites; however evidence of
miscalibration suggests we should be cautious when attempting to generalise these findings.
Future research should include larger collaborations and aim to develop ‘from onset’
population predictions.
NEWS2 is a summary score derived from six physiological parameters, including oxygen
supplementation. Lack of evidence for NEWS2 use in COVID-19 especially in primary care
has been highlighted[9]. The oxygen saturation component of physiological measurements
added value beyond NEWS2 total score and was retained following regularisation for 14-day
endpoints. This suggests some residual association over and above what is captured by the
NEWS2 score, and reinforces Royal College of Physicians guidance that the NEWS2 score
ceilings with respect to respiratory function[42].
Cardiac disease and myocardial injury have been described in severe COVID-19 cases in
China[2, 23]. In our model, blood Troponin-T, a marker of myocardial injury, had additional
salient signal but was only measured in a subset of our cohort at admission, so it was
excluded from our final model. This could be explored further in larger datasets.
Strengths and limitations
Our study provides a risk stratification model for which we obtained generalisable and robust
results across seven national and international sites with differing geographical catchment
and population characteristics. It is among the first to evaluate NEWS2 at hospital admission
for severe COVID-19 outcome and among a handful to externally validate a supplemented
model across multiple sites.
However, some limitations must be acknowledged. First, there are likely to be other
parameters not measured in this study that could substantially improve the risk stratification
model (e.g. radiological features, obesity, or comorbidity load). These parameters could be
explored in future work but were not considered in the present study to avoid limiting the
real-world implementation of the risk stratification model. Second, our models showed better
performance in UK secondary care settings among populations with higher rates of severe
COVID-19 disease. Therefore, further research is needed to investigate the suitability of our
model for primary care settings which have a high prevalence of mild disease severities and
in community settings. This would allow us to capture variability at earlier stages of the
disease and trends in patients not requiring hospital admission. Third, while external
validation across multiple national and international sites represents a key strength, we did
not have access to individual participant data and model development was limited to a single
site (KCH). Although we benefited from existing infrastructure to support rapid data analysis,
we urgently need infrastructure to support data sharing between sites to address some of the
limitations of the present study (e.g. miscalibration) and improve the transferability of these
models. Not only would this facilitate external validation, but more importantly, it would
allow multi-site prediction models to be developed using pooled, individual participant
data[43]. Fourth, our analyses would have excluded patients who experienced severe
COVID-19 outcome at home or at another hospital, after being discharged from a
participating hospital. Fifth, our model was restricted to blood and physiological parameters
measured at hospital admission. This was by design and reflected the aim of developing a
screening tool for risk stratification at hospital admission. However, future studies should
explore the extent to which risk stratification could be improved by incorporating repeated
measures of NEWS2 and relevant biomarkers.
CONCLUSIONS
The NEWS2 early warning score is in near-universal use in UK NHS Trusts since March
2019[15] but little is known about its use for COVID-19 patients. Here we showed that
NEWS2 and age at hospital admission had moderate discrimination for medium-term (14-
day) severe COVID-19 outcome, questioning its use as a tool to guide hospital admission.
Moreover, we showed that NEWS2 discrimination could be improved by adding eight blood
and physiological parameters (supplemental oxygen flow rate, urea, age, oxygen saturation,
CRP, estimated GFR, neutrophil count, neutrophil/lymphocyte ratio) that are routinely
collected and readily available in healthcare services. Thus, this type of model could be
easily implemented in clinical practice and predicted risk score probabilities of individual
patients are easy to communicate. At the same time, although we provided some evidence of
improved discrimination versus NEWS2 and age alone, given miscalibration in external sites
our proposed model should be used as a complement and not as a replacement for clinical
judgment.
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COVID-19 WHO Score 6-8 (ICU/death) N avail. N (%) N avail.
3 days 1276 163 (12.8%) 633
14 days 1276 389 (30.5%) 633
Demographics N avail. N (%) N avail.
Age (median [IQR]) 1276 71.5 [57.1, 82.6] 633
Sex (male) 1276 742 (58.2%) 633
Non-White ethnicity 960 379 (39.5%) 546
Comorbidities N avail. N (%) N avail.
Hypertension 1276 695 (54.5%) 633
Diabetes mellitus 1276 439 (34.4%) 633
Heart Failure 1276 117 (9.2%) 633
Ischaemic Heart Diseases 1276 185 (14.5%) 633
COPD 1276 141 (11.1%) 633
Asthma 1276 174 (13.6%) 633
Chronic Kidney Disease 1276 234 (18.3%) 633
Blood biomarker N avail. Median [IQR] N avail.
Albumin (g/L) 1153 37.0 [33.0, 40.0] 501
C-reactive protein (CRP, mg/L) 1240 80.0 [36.0, 141.6] 545
Urea (mmol/L) 1221 7.1 [4.6, 11.7] 563
Estimated GFR 1254 65.0 [41.0, 86.0] 377
Haemoglobin (g/L) 1223 127.0 [112.0, 141.0] 561
Lymphocyte count (x109/L) 1221 0.9 [0.7, 1.3] 561
Neutrophil count  (x109/L) 1220 5.4 [3.8, 7.7] 560
Neutrophil/lymphocyte ratio 1218 5.6 [3.4, 9.5] 559
Lymphocyte/CRP ratio 1196 1.2 [0.6, 3.2] 559
Platelet count  (x109/L) 1224 213.0 [161.8, 274.0] 560
Physiological parameters N avail. Median [IQR] N avail.
NEWS2 Total Score 1262 2.0 [1.0, 4.0] 529
Heart rate 1273 85.0 [75.0, 94.0] 560
Oxygen saturation 1273 96.0 [95.0, 98.0] 561
Oxygen flow rate (L/min) 1271 0.0 [0.0, 4.0] 260
Respiration rate 1273 19.0 [18.0, 21.0] 561
Systolic blood pressure 1273 125.0 [112.0, 139.0] 555
Diastolic blood pressure 1273 71.0 [62.0, 80.0] 555
Temperature 1273 36.9 [36.6, 37.4] 558
Table 1: Patient characteristics of the training/validation cohorts
Training cohort Validation cohorts (n=6237)
KCH  (n=1276) UHS (n=633)
Notes.
1Measured as ‘Cardiovascular disease’ at UCH because separate measures of ‘Heart Failure’ and ‘Ischaemic Heart Diseases’ were unavailable.
2Measured as overall ‘Heart disease’ in Wuhan cohort.
N (%) N avail. N (%) N avail. N (%)
109 (17.2%) 411 120 (29.0%) 988 289 (29.3%)
223 (35.2%) 411 171 (42.0%) 988 391 (39.6%)
N (%) N avail. N (%) N avail. N (%)
73.0 [56.0, 84.0] 411 66.0 [53.0, 79.0] 988 59.0 [46.0,75.0]
364 (57.5%) 411 252 (61.0%) 988 581 (58.8%)
55 (10.0%) 390 156 (40.0%) 817  607 (74.3%)
N (%) N avail. N (%) N avail. N (%)
321 (50.7%) 411 172 (42.0%) 988 309 (31.3%)
163 (25.8%) 411 105 (26.0%) 988 286 (28.9%)
137 (21.6%) 410 -- 988 52 (5.3%)
152 (24.0%) 409 108 (26.0%)1 -- --
115 (18.2%) 409 27 (6.6%) 988 64 (6.5%)
112 (17.7%) 409 41 (10.0%) 988 85 (8.6%)
111 (17.5%) 410 40 (9.8%) 988 110 (11.1%)
Median [IQR] N avail. Median [IQR] N avail. Median [IQR]
32.0 [29.0, 36.0] 390 38.0 [35.0, 42.0] 863 36.0 [31.0, 40.0]
75.0 [25.0, 150.0] 403 97.0 [45.0, 179.0] 974 76.5 [25.0, 153.8]
6.95 [4.8, 10.6] 375 6.0 [4.0, 9.4] 489 7.4 [4.6, 12.5]
62.0 [40.0, 81.0] 407 77.0 [54.0, 96.0] 965 74.0 [49.0, 100.0]
128.0 [111.0, 143.0] 410 130.0 [112.0, 143.0] 987 125.0 [108.0, 139.0]
1.0 [0.7, 1.4] 410 0.9 [0.6, 1.4] 987 0.9 [0.6, 1.3]
5.8 [4.2, 8.8] 410 5.9 [3.9, 8.2] 986 5.0 [3.5, 8.1]
5.8 [3.4, 10] 410 6.0 [4.0, 10.0] 986 5.6 [3.2, 10.1]
1.3 [0.5, 4.6] 402 1.0 [0.4, 2.4] 0.0 [0.0, 0.0]
231 [176.8, 303.5] 409 221.0 [169.0, 280.0] 986 209.0 [161.0, 275.8]
Median [IQR] N avail. Median [IQR] N avail. Median [IQR]
3.0 [2.0, 5.0] 404 5.0 [3.0, 7.0] 744 3.0 [1.0, 5.0]
90.5 [82.0, 102.0] 410 94.0 [81.0, 107.0] 752 85.0 [75.0, 95.0]
97.0 [96.0, 99.0] 410 96.0 [94.0, 98.0] 712 96.0 [95.0, 97.0]
3.0 [2.0, 8.0] 403 2.0 [0.0, 10.0] 978 0.0 [0.0, 0.0]
20.0 [19.0, 24.0] 410 24.0 [20.0, 28.0] 755 19.0 [18.0, 22.0]
137.0 [123.0, 152.0] 411 131.0 [115.0, 143.0] 751 125.0 [115.0, 140.0]
78.0 [70.0, 85.0] 411 73.0 [64.0, 81.0] 751 74.0 [66.0, 81.0]
36.9 [36.7, 37.5] 410 37.3 [36.8, 38.1] 750 36.9 [36.4, 37.5]
Table 1: Patient characteristics of the training/validation cohorts
Validation cohorts (n=6237)
UHS (n=633) UCH (n=411) GSTT (n=988)
Notes.
1Measured as ‘Cardiovascular disease’ at UCH because separate measures of ‘Heart Failure’ and ‘Ischaemic Heart Diseases’ were unavailable.
2Measured as overall ‘Heart disease’ in Wuhan cohort.
N avail. N (%) N avail. N (%) N avail.
190 32 (16.8%) 2815 58 (2.1%) 1037
190 56 (29.5%) 2815 118 (4.2%) 1037
N avail. N (%) N avail. N (%) N avail.
190 73.5 [59.3, 82.0] 2815 60.0 [50.0, 68.0] 1037
190 120 (63.1%) 2815 1437 (51.0%) 1037
190 46 (24.2%) 2815 2815 (100%) 892
N avail. N (%) N avail. N (%) N avail.
190 117 (61.6%) 2815 821 (29.2%) 1037
190 71 (37.4%) 2815 371 (13.2%) 1037
190 33 (17.4%) 2815 236 (8.4%)2 1037
190 52 (27.4%) -- -- 1037
190 41 (21.6%) 2815 17 (0.6%) 1037
190 27 (14.2%) -- -- 1037
190 59  (31.1%) 2815 56 (2.0%) 1037
N avail. Median [IQR] N avail. Median [IQR] N avail.
190 30.0 [27.0, 33.0] 2404 38.1 [35.1, 40.5] 993
190 77.0 [36.3, 138.3] 2393 2.3 [0.8, 9.0] 970
-- -- -- -- 1018
190 68.0 [43.3. 88.0] 2433 103.1 [88.2, 117.5] 757
190 129.0 [110.0, 141.0] 2584 124.0 [113.0, 135.0] 1009
190 0.9 [0.6, 1.2] 2584 1.5 [1.1, 1.9] 1011
190 5.2 [3.5, 7.4] 2584 3.5 [2.7, 4.7] 1011
190 5.7 [3.6, 9.8] 2584 2.3 [1.7, 3.5] 1011
190 1.1 [0.5, 2.7] 2362 0.7 [0.1, 2.0] 962
190 207.5 [150.3, 268.5] 2584 223.0 [179.8, 273.0] 1008
N avail. Median [IQR] N avail. Median [IQR] N avail.
190 3.0 [2.0, 5.0] 2804 1.0 [0.0, 3.0] 1019
190 82.0 [71.0, 95.0] 2812 81.0 [76.9, 85.8] 1028
190 95.0 [94.0, 96.0] 2797 97.8 [97.0, 98.2] 1029
190 2.0 [0.0, 3.0] -- -- 1017
190 20.0 [18.0, 21.0] 2811 20.0 [19.0, 21.0] 1020
190 123.0  [111.0, 140.8] 1431 120.0 [110.0, 128.0] 1022
190 72.0 [64.3,  82.0] 1433 71.0 [65.0, 78.0] 1022
190 37.2 [36.7, 37.9] 2815 36.5 [36.3, 36.7] 1029
Table 1: Patient characteristics of the training/validation cohorts
Validation cohorts (n=6237)
UHBW (n=190) Wuhan (n=2815) UHB (n=1037)
Notes.
1Measured as ‘Cardiovascular disease’ at UCH because separate measures of ‘Heart Failure’ and ‘Ischaemic Heart Diseases’ were unavailable.
2Measured as overall ‘Heart disease’ in Wuhan cohort.
N (%) N avail. N (%)
169 (16.3%) 163 27 (16.3%)
310 (29.9%) 163 39 (23.9%)
N (%) N avail. N (%)
70.0 [57.0, 82.0] 163 60.0 [48.0-74.0]
573 (55.3%) 163 95 (58.3%)
306 (34.3%) -- --
N (%) N avail. N (%)
637 [61.4%) 163 55 (33.7%)
358 (34.5%) 163 27 (16.6%)
178 (17.2%) 163 15 (9.2%)
245 (23.6%) 163 21 (12.9%)
152 (14.7%) -- --
169 (16.3%) -- --
274 (26.4%) 163 9 (5.5%) 
Median [IQR] N avail. Median [IQR]
32.0 [28.0, 35.0] 120 39.0 [36.0-43.0]
89.0 [33.2, 157.0] 163 48.0 [16.0-113.0]
6.8 [4.6, 11.8] 154 5.5 [4.3-7.5]
54.0 [29.0, 72.0] 163 84.0 [57.0-99.0]
130.0 [113.0, 144.0] 163 139.0[129.0-148.0]
0.9 [0.7, 1.4] 153 1.1 [0.8-1.5]
5.5 [3.8, 8.2] 153 4.4 [3.0-7.1]
5.6 [3.2, 10.2] 153 4.3 [2.4-7.7]
1.1 [0.5, 3.3] -- --
218.0 [165.0, 287.2] 163 205.0 [160.0-279.0]
Median [IQR] N avail. Median [IQR]
4.0 [2.0, 7.0] 163 5.0 [3.0-7.0]
90.0 [79.0, 104.0] 160 89.5 [75.3-100.8]
96.0 [94.0, 98.0] 163 95.0 [92.0-97.0]
0.0 [0.0, 4.0] 125 1.0 [0.0-2.0]
20.0 [18.0, 25.0] 160 24.0 [20.0-28.0]
128.0 [113.0, 144.0] 160 129 [116.0-142.8]
75.0 [67.0, 84.0] 160 77.0 [69.0-87.0]
36.8 [36.2, 37.5] 162 37.2 [36.5-38.3]
Validation cohorts (n=6237)
UHB (n=1037) Oslo (n=163)
Table S1: SNOMED terms
SNOMED concept name SNOMED concept IDs
Diabetes S-230572002, S-44054006, S-237599002, S-49455004
Heart Failure S-42343007, S-426263006, S-48447003, S-418304008, S-10633002
IHD S-401314000, S-194828000, S-233839009, S-414545008
S-394659003, S-1755008, S-413838009Hypertension S-59621000
COPD S-13645005, S-313297008
Asthma S-195967001
CKD S-433144002, S-90688005, S-709044004
Table S2: F1, precision and recall for NLP comorbidity detection
 TP F1 P R SNOMED terms
Diabetes mellitus 73 0.936 0.924 0.948
S-230572002, S-44054006,
S-237599002, S-49455004









Hypertension 84 0.883 0.988 0.778 S-59621000
COPD 14 0.967 0.933 1 S-13645005, S-313297008
Asthma 11 1 1 1 S-195967001
CKD 15 0.938 0.938 0.938
S-433144002, S-90688005,
S-709044004
MedCATTrainer was used to collect manual annotations for 146 clinical documents totalling
4343 annotations. Each co-morbidity is defined using one or more SNOMED terms. Predicted
true positive labels (TP), precision (P), recall (R), F1-score (F1) are shown for these aggregated






NEWS2 score 1262 2.10 [1.83, 2.40] <0.001 2.13 [1.86, 2.44]
Oxygen flow rate 1271 1.92 [1.70, 2.17] <0.001 1.97 [1.74, 2.22]
Respiratory rate 1273 1.65 [1.45, 1.86] <0.001 1.65 [1.45, 1.87]
CRP 1240 1.64 [1.44, 1.87] <0.001 1.65 [1.45, 1.88]
Lymphocyte/CRP ratio 1196 0.63 [0.55, 0.73] <0.001 0.63 [0.54, 0.72]
Oxygen saturation 1273 0.65 [0.57, 0.73] <0.001 0.63 [0.56, 0.72]
Neutrophil count 1220 1.41 [1.25, 1.60] <0.001 1.42 [1.25, 1.61]
Urea 1221 1.40 [1.23, 1.60] <0.001 1.42 [1.23, 1.64]
Neutrophil/lymphocyte ratio 1218 1.38 [1.21, 1.57] <0.001 1.39 [1.21, 1.58]
Heart rate 1273 1.34 [1.18, 1.52] <0.001 1.35 [1.19, 1.53]
Estimated GFR 1254 0.78 [0.68, 0.88] <0.001 0.76 [0.66, 0.88]
Albumin 1153 0.80 [0.70, 0.92] 0.002 0.81 [0.71, 0.92]
Temperature 1273 1.21 [1.07, 1.37] 0.004 1.21 [1.07, 1.38]
Platelet count 1224 0.88 [0.78, 1.01] 0.075 0.88 [0.78, 1.01]
Diastolic blood pressure 1273 0.89 [0.78, 1.00] 0.075 0.89 [0.78, 1.01]
Systolic blood pressure 1273 0.91 [0.81, 1.03] 0.157 0.91 [0.80, 1.03]
Lymphocytes 1221 0.93 [0.82, 1.06] 0.279 0.93 [0.82, 1.06]
Hemoglobin 1223 1.04 [0.92, 1.19] 0.505 1.07 [0.94, 1.22]
Notes.
Table S3: Logistic regression models for each blood and physiological measure tested separately in the KCH training cohort, for 14- and 3-day ICU/death
14 day ICU/death
N avail.
Model 1: Age, sex only1 Model 2: + comorbidities2
Continuous predictors were standardised (mean = 0; standard deviation = 1), therefore, odds ratios represent one standard deviation change in the respective parameter,
each tested in a separate model. 1Adjusted for age and sex only. 2Additionally adjusted for comorbidities (hypertension, diabetes, heart diseases, respiratory diseases and






<0.001 2.66 [2.25, 3.16] <0.001 2.65 [2.23, 3.15] <0.001
<0.001 2.22 [1.92, 2.56] <0.001 2.25 [1.94, 2.60] <0.001
<0.001 1.83 [1.59, 2.10] <0.001 1.81 [1.58, 2.09] <0.001
<0.001 1.89 [1.59, 2.24] <0.001 1.92 [1.61, 2.28] <0.001
<0.001 0.58 [0.47, 0.71] <0.001 0.57 [0.47, 0.71] <0.001
<0.001 0.51 [0.44, 0.60] <0.001 0.49 [0.42, 0.58] <0.001
<0.001 1.53 [1.31, 1.80] <0.001 1.54 [1.31, 1.81] <0.001
<0.001 1.38 [1.17, 1.63] <0.001 1.48 [1.23, 1.78] <0.001
<0.001 1.44 [1.21, 1.73] <0.001 1.45 [1.21, 1.74] <0.001
<0.001 1.54 [1.30, 1.82] <0.001 1.54 [1.30, 1.82] <0.001
<0.001 0.87 [0.73, 1.03] 0.125 0.82 [0.67, 1.00] 0.058
0.002 0.76 [0.64, 0.90] 0.002 0.75 [0.63, 0.89] 0.002
0.003 1.23 [1.04, 1.44] 0.018 1.23 [1.05, 1.45] 0.016
0.080 1.05 [0.89, 1.24] 0.630 1.04 [0.88, 1.23] 0.698
0.080 0.80 [0.67, 0.95] 0.016 0.79 [0.66, 0.94] 0.012
0.148 0.95 [0.80, 1.13] 0.625 0.94 [0.79, 1.12] 0.522
0.282 1.01 [0.85, 1.19] 0.942 1.00 [0.84, 1.19] 0.980
0.329 1.20 [1.01, 1.44] 0.052 1.21 [1.00, 1.45] 0.057
Table S3: Logistic regression models for each blood and physiological measure tested separately in the KCH training cohort, for 14- and 3-day ICU/death
14 day ICU/death 3 day ICU/death
Model 2: + comorbidities2 Model 1: Age, sex only1 Model 2: + comorbidities2
Continuous predictors were standardised (mean = 0; standard deviation = 1), therefore, odds ratios represent one standard deviation change in the respective parameter,
each tested in a separate model. 1Adjusted for age and sex only. 2Additionally adjusted for comorbidities (hypertension, diabetes, heart diseases, respiratory diseases and
chronic kidney disease). 3FDR-corrected P-values based on the Benjamini-Hochberg correction.
 Outcome Sample  Model
No.
features
NEWS2 + age 2
All features 9
NEWS2 + age 2
All features 9
NEWS2 + age 2
All features 2
NEWS2 + age 2
All features 2
NEWS2 + age 2
All features 2
Table S4: Internally validated discrimination for KCH training sample based on nested repeated cross-validation
14-day ICU/death1
Subset 1: Patients with data on
ethnicity (n=960)




Subset 1: Patients with
non-missing ethnicity (n=960)
Subset 2: Excluding nosocomial
patients (n=1123)
Notes.
1 Sensitivity/specificity calculated at 30% probability threshold;
2 Calculated at 20% probability threshold.
AUC based on repeated, nested cross-validation (inner loop: 10 folds; outer loop = 10 folds/1000 repeats).









0.694 [0.667, 0.721] 0.197 [0.191, 0.204] 0.848 [0.811, 0.889] 0.364 [0.324, 0.405]
0.728 [0.703, 0.754] 0.189 [0.183, 0.195] 0.806 [0.768, 0.845] 0.496 [0.459, 0.533]
0.721 [0.701, 0.744] 0.189 [0.184, 0.195] 0.809 [0.775, 0.842] 0.474 [0.444, 0.507]
0.748 [0.727, 0.770] 0.183 [0.177, 0.188] 0.780 [0.743, 0.815] 0.539 [0.503, 0.571]
0.764 [0.737, 0.794] 0.114 [0.108, 0.120] 0.967 [0.871, 1.000] 0.286 [0.000, 0.461]
0.789 [0.763, 0.819] 0.110 [0.103, 0.116] 0.856 [0.793, 0.933] 0.534 [0.475, 0.617]
0.763 [0.732, 0.796] 0.114 [0.107, 0.122] 0.958 [0.857, 1.000] 0.363 [0.211, 0.473]
0.774 [0.740, 0.810] 0.110 [0.102, 0.118] 0.838 [0.739, 0.950] 0.578 [0.429, 0.669]
0.769 [0.738, 0.798] 0.119 [0.113, 0.126] 1.000 [0.971, 1.000] 0.150 [0.000, 0.187]
0.796 [0.767, 0.825] 0.115 [0.108, 0.122] 0.940 [0.888, 1.000] 0.343 [0.180, 0.483]
Table S4: Internally validated discrimination for KCH training sample based on nested repeated cross-validation
Notes.
1 Sensitivity/specificity calculated at 30% probability threshold;
2 Calculated at 20% probability threshold.
AUC based on repeated, nested cross-validation (inner loop: 10 folds; outer loop = 10 folds/1000 repeats).
Missing values imputed at each outer loop with k-Nearest Neighbours (KNN) imputation.

Table S5: Univariate logistic regression models for sensitivity analyses showing odds ratios of ICU/death at 3- and 14-days for subsets of the training cohort
 
 
 N OR [95% CI] P-value N OR [95% CI]
NEWS2 score 948 2.07 [1.78, 2.41] <0.001 1109 2.27 [1.96, 2.63]
Oxygen flow rate 955 1.80 [1.57, 2.07] <0.001 1118 2.01 [1.77, 2.29]
Oxygen saturation 957 0.60 [0.51, 0.69] <0.001 1120 0.63 [0.55, 0.72]
CRP 932 1.71 [1.47, 1.99] <0.001 1092 1.61 [1.40, 1.85]
Respiratory rate 957 1.61 [1.40, 1.85] <0.001 1120 1.66 [1.46, 1.89]
Lymphocyte/CRP ratio 900 0.59 [0.50, 0.71] <0.001 1056 0.64 [0.55, 0.75]
Heart rate 957 1.36 [1.18, 1.56] <0.001 1120 1.39 [1.22, 1.59]
Neutrophil count 918 1.49 [1.29, 1.73] <0.001 1075 1.34 [1.17, 1.54]
Neutrophil/lymphocyte ratio 917 1.47 [1.26, 1.71] <0.001 1074 1.33 [1.15, 1.53]
Urea 917 1.38 [1.17, 1.62] <0.001 1084 1.36 [1.17, 1.58]
Albumin 866 0.81 [0.69, 0.94] 0.008 1036 0.80 [0.68, 0.93]
Diastolic blood pressure 957 0.91 [0.79, 1.05] 0.22 1120 0.88 [0.77, 1.00]
Temperature 957 1.22 [1.06, 1.41] 0.008 1120 1.28 [1.12, 1.46]
Hemoglobin 921 1.07 [0.92, 1.25] 0.374 1079 1.11 [0.95, 1.28]
Estimated GFR 944 0.80 [0.69, 0.93] 0.003 1108 0.78 [0.68, 0.90]
Systolic blood pressure 957 0.90 [0.78, 1.04] 0.177 1120 0.93 [0.82, 1.06]
Platelet count 922 0.88 [0.76, 1.03] 0.134 1079 0.92 [0.79, 1.06]
Lymphocytes 920 0.93 [0.81, 1.07] 0.281 1076 0.92 [0.81, 1.05]
Notes. 
All models in this table are adjusted for age, sex, and comorbidties.
14-day ICU/death
Subset 1: Adjusted for ethnicity,
in the subset of patients with
non-missing ethnicity
Subset 2: Excluding nosocomial
patients
Table S5: Univariate logistic regression models for sensitivity analyses showing odds ratios of ICU/death at 3- and 14-days for subsets of the training cohort
P-value N OR [95% CI] P-value N OR [95% CI] P-value
<0.001 948 2.50 [2.06, 3.03] <0.001 1109 2.75 [2.29, 3.31] <0.001
<0.001 955 2.12 [1.80, 2.50] <0.001 1118 2.30 [1.97, 2.67] <0.001
<0.001 957 0.47 [0.39, 0.57] <0.001 1120 0.51 [0.43, 0.60] <0.001
<0.001 932 1.97 [1.60, 2.42] <0.001 1092 1.86 [1.55, 2.23] <0.001
<0.001 957 1.68 [1.43, 1.96] <0.001 1120 1.85 [1.60, 2.14] <0.001
<0.001 900 0.58 [0.46, 0.74] <0.001 1056 0.60 [0.48, 0.74] <0.001
<0.001 957 1.59 [1.31, 1.92] <0.001 1120 1.53 [1.29, 1.83] <0.001
<0.001 918 1.63 [1.35, 1.97] <0.001 1075 1.55 [1.30, 1.85] <0.001
<0.001 917 1.50 [1.21, 1.85] <0.001 1074 1.41 [1.16, 1.71] <0.001
<0.001 917 1.41 [1.15, 1.74] 0.002 1084 1.43 [1.18, 1.73] <0.001
0.005 866 0.75 [0.61, 0.92] 0.009 1036 0.69 [0.56, 0.84] <0.001
0.071 957 0.80 [0.65, 0.99] 0.056 1120 0.77 [0.64, 0.93] 0.01
<0.001 957 1.19 [0.99, 1.43] 0.082 1120 1.22 [1.03, 1.44] 0.025
0.215 921 1.23 [1.00, 1.52] 0.071 1079 1.19 [0.97, 1.45] 0.116
0.005 944 0.92 [0.75, 1.12] 0.137 1108 0.87 [0.72, 1.04] 0.116
0.282 957 0.95 [0.78, 1.15] 0.615 1120 0.98 [0.82, 1.17] 0.821
0.271 922 1.12 [0.93, 1.36] 0.265 1079 1.14 [0.95, 1.37] 0.167
0.222 920 1.04 [0.86, 1.27] 0.727 1076 1.04 [0.87, 1.24] 0.778
14-day ICU/death 3-day ICU/death 
Subset 2: Excluding nosocomial
patients
Subset 1: Adjusted for ethnicity,
in the subset of patients with
non-missing ethnicity
Subset 2: Excluding nosocomial
patients
Table S6: Discrimination for all models in training and validation cohorts, including alternative baseline model of ‘NEWS2 only’.
Endpoint Model AUC Sens.1 Spec.1
NEWS2 only 0.760 0.971 0.301
NEWS2 + age 0.764 0.967 0.286
All features 0.789 0.856 0.534
NEWS2 only 0.672 1.000 0.000
NEWS2 + age 0.700 0.778 0.478
All features 0.735 0.735 0.592
NEWS2 only 0.772 0.361 0.926
NEWS2 + age 0.772 0.361 0.926
All features 0.815 0.296 0.963
NEWS2 only 0.734 0.465 0.839
NEWS2 + age 0.728 0.532 0.799
All features 0.771 0.594 0.821
NEWS2 only 0.755 0.225 0.945
NEWS2 + age 0.755 0.225 0.945
All features 0.831 0.125 0.986
NEWS2 only 0.697 0.474 0.817
NEWS2 + age 0.729 0.503 0.788
All features 0.809 0.509 0.896
NEWS2 only 0.717 0.035 0.983
NEWS2 + age 0.717 0.035 0.983
All features 0.716 0.007 0.999
NEWS2 only 0.734 0.123 0.972
NEWS2 + age 0.686 0.156 0.946
All features 0.762 0.136 0.972
NEWS2 only 0.768 0.519 0.853
NEWS2 + age 0.768 0.519 0.853
All features 0.800 0.259 0.993
NEWS2 only 0.759 0.641 0.790
NEWS2 + age 0.786 0.615 0.774
All features 0.837 0.564 0.871
NEWS2 only 0.687 0.125 0.968
NEWS2 + age 0.687 0.125 0.968
All features 0.704 0.063 0.994
NEWS2 only 0.632 0.143 0.888
NEWS2 + age 0.623 0.250 0.858
All features 0.693 0.286 0.903
NEWS2 only 0.732 0.110 0.973
NEWS2 + age 0.732 0.110 0.973
All features 0.781 0.092 0.985
NEWS2 only 0.743 0.202 0.988
























All features 0.770 0.345 0.963
NEWS2 only 0.747 0.000 1.000
NEWS2 + age 0.747 0.000 1.000
All features 0.747 0.000 1.000
NEWS2 only 0.744 0.035 0.996
NEWS2 + age 0.815 0.122 0.988
All features 0.864 0.009 1.000
Notes.
1 Thresholds for sensitivity and specificity were 20% and 30% for 3-day and 14-day endpoints, respectively.







AUC = Area Under the Receiver Operating Characteristic curve; TP = true positives; TN = true negatives; FP = false
positives; FN = false negatives; Sens. = Sensitivity; Spec. = Specificity; PPV = Positive Predictive Value; NPV = Negative
Predictive Value.


















































AUC = Area Under the Receiver Operating Characteristic curve; TP = true positives; TN = true negatives; FP = false
positives; FN = false negatives; Sens. = Sensitivity; Spec. = Specificity; PPV = Positive Predictive Value; NPV = Negative
Predictive Value.

